SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced the presentation of preclinical data demonstrating that HE3286, a derivative of an endogenous hormone the Company believes is central to regulating glucose metabolism, produced glucose lowering activity and increased insulin sensitivity in preclinical models of type 2 diabetes. Findings suggest HE3286, an oral synthetic hormone, acts through a new mechanism of action and represents a potentially new class of insulin sensitizers for the treatment of type 2 diabetes. The data are being presented at the Diabetes: Molecular Genetics, Signaling Pathways and Integrated Physiology Conference, sponsored by Keystone Symposia, January 14-19, 2007, in Keystone, Colorado.
